Many progresses for the treatment of multiple myeloma have been made since last decade.The application of novel target agents has brought the treatment of multiple myeloma into a new era.The outcomes of multiple myeloma have also been greatly improved with mechanism-based combinations of various agents.It is emphasized that clinicians should better understand the biological characteristics of myeloma cells and the anti-myeloma mechanisms underlined.In this review,the author will review the current status and make a prospective discussion in this field.

In present study,we detected HLA-DR antigens on monocytes of 28 patients with mutiplemyelomas (MM) and 20 normal controls with indirect immunofluorescent staining and flow cy-tometric technique.It was descovered that HLA-DR~+ monocytes of patients (33.63?16.24%)were greatly lower than these of normal controls (61.45?10.1% ) (P

Diagnostic Imaging ; Humans ; Multiple Myeloma ; diagnosis ; therapy

Humans ; Multiple Myeloma ; Neoplasm Recurrence, Local

Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma ; pathology ; therapy ; Neoplasm Staging ; Transplantation, Autologous

Purpose:To explore the in vitro effects of apoptosis induction of 2-methoxyestradiol(2ME2),an estrogen derivative on primary myeloma cells and hematopoietic precursors from multiple myeloma patients. Methods:The primary myeloma cells and hematopoietic precursors from 14 multiple myeloma patients were examined determine apoptosis cells in situ by terminal-deoxynucleotidyl transferase mediated dUTP nick end labeling(TUNEL)assay. Results:After co-cultured with different concentrations (1,4,16?mol/L) 2 ME2 for 48h respectively,apoptotic ratios of myeloma cells were 10.5? 1.2%,21.2?2.3%,36.8?3.6% respectively ,which shows a concentration- dependence.In comparision with the control group,the difference is of statistical significance(P0.05). Conclusions:2ME2 could electively induce apoptosis of primary myeloma cells from myeloma patients and has little apoptotic effect on granulocytic,erythrocytic and lymphocytic cells in the bone marrow.

Autologous stem cell transplantation (ASCT) is the standard frontline therapy for newly diagnosed multiple myeloma (MM) in patients younger than 65 years in the era of conventional chemotherapy. The use of novel drug-based chemotherapy in the in-duction, consolidation, and maintenance phases of chemotherapy has significantly improved the response rates of patients. Thus, wheth-er or not ASCT is still necessary in the era of new drugs has become controversial. Currently available data supported that ASCT should be the frontline therapy for qualified newly diagnosed MM patients and that new drugs may be applied before and after ASCT to further improve the response rate and prolong the progression-free survival of patients. Further prospective clinical trials should be conducted to clarify the role of ASCT in MM and optimize the treatment strategies involving ASCT in the era of new drugsto cure myeiona.

Objective To investigate the clinical efficacy of warm needling moxibustion in treating peptic ulcer.Methods Sixty patients with peptic ulcer were randomly allocated to treatment and control groups, 30 cases each. The treatment group received warm needling moxibustion and the control group took omeprazole and ranitidine. The clinical therapeutic effects were compared between the two groups after two months of treatment.Results The cure rate and the total efficacy rate were 53.3% and 93.3%, respectively, in the treatment group and 33.3% and 76.7%, respectively, in the control group; there were statistically significant differences between the two groups (P<0.05). The efficacy rates for symptoms (gastralgia, stomach fullness, belching and acid regurgitation, and nausea and vomiting) were 93.3%, 89.3%, 88.5% and 91.7%.Conclusion Warm needling moxibustion is an effective way to treat peptic ulcer.

Multiple myeloma (MM) remains an incurable disease at present. In past decade, the efficacies of treatment and patients' survivals have been greatly improved due to the application of high dose chemotherapy followed by stem cell transplantation, novel agents and their combinations. To further improve the outcomes of patients with MM, we should emphasize on exploration of the new treatment strategies, individualization of regimens and development of new targets.